India, Aug. 21 -- Shanghai Henlius Biotech Inc. (2696.HK), a global biopharmaceutical company, reported higher revenue and profit for the first half of 2026, driven by growth across its core products and expanding international commercialization.
The Chinese company develops biologic therapies across oncology, autoimmune diseases and other therapeutic areas and continues to advance its global commercialization and innovation strategy.
H1 Financial Highlights:
Net profit increased 10.3% to RMB430.44 million, or RMB0.79 per share, from RMB390.13 million, or RMB0.72 per share, in the first half of 2025.
Revenue rose 27.3% to RMB3.588 billion from RMB2.819 billion a year earlier.
Non-IFRS profit increased 46.7% to RMB572.3 million, while a...